Video
ERCP with ballon dilation of the papilla and subsequent cholangioscopy with electro-hydraulic lithotripsy of the bile duct stone
Live endoscopy from the HSK Dr. Horst Schmidt Hospitals in Wiesbaden in collaboration with „Video Journal and Encyclopedia of GI Endoscopy“. Recording in the context of the Falk Symposium 185 „Interfaces and Controversies in Gastroenterology“ on October 3rd – 4th, 2012.
©2013 Elsevier. All rights reserved. Wirth the friendly assistance of Falk Foundation e.V., Freiburg.
Presented by:
Jürgen Pohl, HSK Dr. Horst-Schmidt-Kliniken Wiesbaden, Germany;
Chris Mulder, Vrieje Universiteit Amsterdam, The Netherlands
Summary:
This is the case of a 69-year-old woman with jaundice and intermittent abdominal pain. ERCP in this patient showed an impacted bile duct stone that could not be retrieved. An attempt to capture the stone with a lithotripsy basket also failed.
In a next step, ERCP with balloon dilation of the papilla is performed to obtain adequate access for direct cholangioscopy and subsequent electrohydraulic lithotripsy of the stone.
Take home messages:
- Direct cholangioscopy is an easy and attractive technique for evaluation and treatment of pathologies in the common bile duct. It is also very useful for electrohydraulic lithotripsy of bile duct stones under direct visualization.
- To reduce the potential risk of common bile duct injury there are a few important advices:The first is: Always keep intraductal gas insufflation at an absolute minimum.
Moreover, it is strongly advised to perform a decent sphincterotomy that might be combined with balloon dilation up to 10 mm prior to cholangioscopy.
This allows adequate efflux of the gas and might prevent a ventile effect with subsequent gas embolization.
Please switch on your loudspeakers!
Link to Falk Mediacenter:
http://media.falkfoundation.de/index.php?id=84&L=1
Link to the video directly:
http://media.drfalkpharma.de/fileadmin/media/130502_EHL_FINAL.mp4
Preview images:
580 x 350 pixels
http://www.drfalkpharma.de/fileadmin/media/Video/ERCP_Ballondilatation_580.png
Latest research in brief:
Description field (to be displayed at the end of the structural element):
Editor: Prof. W. Kreisel, Medical University Hospital, 79106 Freiburg, Germany
Bowel
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Bowel-Logo-FGR.gif
Text:
Lutgens MWMD et al, Inflamm Bowel Dis. 2013;19(4):789–99
The risk of colorectal cancer in patients with inflammatory bowel disease is declining. However, the risk of colorectal cancer is significantly higher in patients with longer disease duration, extensive disease, and inflammatory bowel disease diagnosis at young age.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24218
Text:
Casanova MJ et al, Am J Gastroenterol. 2013;108(3):433–40
The treatment with thiopurines and anti-TNF-antibodies does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24219
Text:
van Schaik FDM et al, Gut. 2013;62(5):683–8
A panel of serological markers is able to predict the development of Crohn’s disease and ulcerative colitis in individuals from a low-risk population.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24222
Liver
Biliary Tracts
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Liver-Logo-FGR.gif
Text:
Kumada T et al, J Hepatol. 2013;58(3):427–33
Nucleos(t)ide analogue therapy reduces the risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24220
Text:
Ogawa E et al, J Hepatol. 2013;58(3):495–501
Sustained virological response and complete viral suppression during treatment with relapse (transient virological response) were associated with a lower risk of hepatocellular carcinoma development when compared with non-virological response.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24217
Text:
Terrault NA et al, Hepatology. 2013;57(3):881–9
Among monogamous heterosexual couples the risk of HCV transmission is extremely low, it amounts to 0.07% per year.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24221
Oesophagus
Stomach
Duodenum
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Oeso-Logo-FGR.gif
Text:
Chan FKL et al, Gastroenterology. 2013;144(3):528–35
The long-term incidence of recurrent ulcer bleeding with low-dose aspirin (ASA) use is low after Helicobacter pylori infection is eradicated. ASA users without current or past Helicobacter pylori infections who develop ulcer bleeding have a high risk of recurrent bleeding. Tests for Helicobacter pylori infection can be used to assign high-risk ASA users to groups that require different gastroprotective strategies.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24213
Text:
Zhou X et al, Eur J Gastroenterol Hepatol. 2013;25(4):460–8
These data suggest that asthmatics have a significantly lower rate of Helicobacter pylori infection. Further studies should be carried out to determine the relation between this bacterium and allergic disorders.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24223
Text:
Kastelein F et al, Clin Gastroenterol Hepatol. 2013;11(4):382–8
In this multicenter prospective cohort study, proton-pump inhibitor use was associated with a reduced risk of neoplastic progression in patients with Barrett’s esophagus.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24216
Pancreas
http://www.drfalkpharma.de/fileadmin/media/logos_falk/abstracts/Panc-Logo-FGR.gif
Text:
Sadr-Azodi O et al, JAMA Intern Med. 2013;173(6):444–9
Current oral glucocorticoid use is associated with a slightly increased risk of acute pancreatitis.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18004#c24215
Current Falk literature:
Diet and Nutrition in
Crohn’s Disease and
Ulcerative Colitis
Important Questions – Real Answers
Authors: J. Stein, C. Bott
(62 pages)
Revised edition 2014
S84e
Picture:
PDF:
http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Patientenratgeber/PDF/S84e_21-12-13.pdf
Order by email (Please replace text by your email address):